Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
USA
Regulatory Approval:
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Rezdiffra (resmetirom) is a liver-directed THR-β selective agonist that increases liver fat metabolism and reduces liver inflammation and fibrosis. It is indicated, along with diet and exercise, for the treatment of:
This indication is approved under accelerated approval; continued approval may depend on results from confirmatory trials. Rezdiffra is a prescription medicine and must be used under the supervision of a qualified hepatologist or gastroenterologist.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Rezdiffra (resmetirom) tablets may be imported in the patient's name only, by patients or government hospitals, in line with India's import regulations for unapproved medicines. The following documentation is required:
The order is confirmed only after receipt and verification of a valid prescription from the doctor and, if applicable, an import permit.
Rezdiffra (resmetirom tablets) is a prescription medicine that legally requires a doctor's prescription to be dispensed. As of current publicly available information, Rezdiffra is not commercially marketed in India.
However, patients in India can legally access Rezdiffra through the Named Patient Program (NPP) — an import provision that allows patients to receive medicines approved in other countries but not yet marketed in India, under a doctor's prescription and proper regulatory documentation.
Rezdiffra received US FDA accelerated approval in March 2024 for the treatment of MASH with moderate to advanced liver fibrosis, ensuring full transparency throughout the process.
Rezdiffra can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others.
Rezdiffra is sourced directly from authorized channels in the country of origin and shipped to India under GDP-compliant logistics to preserve product integrity from dispatch to delivery.
Named Patient Program supports access to Rezdiffra for patients with MASH across major cities in India, coordinating documentation, sourcing, and delivery with treating hepatologists.
Patients in Mumbai can access Rezdiffra through NPP with support from treating hepatologists and gastroenterologists at the city's leading liver centers.
In Delhi, NPP coordinates with hospitals and specialty liver clinics to facilitate timely access to Rezdiffra.
Bangalore's hepatology and gastroenterology centers work with NPP to support patients requiring Rezdiffra.
Patients in Chennai can access Rezdiffra through NPP, with coordination between treating doctors and the program's regulatory and logistics team.
Hyderabad's liver disease centers support diagnosis and access coordination for Rezdiffra through NPP.
NPP facilitates access to Rezdiffra for patients in Kolkata under the guidance of treating specialists.
Patients in Pune can access Rezdiffra through NPP with prescription-based coordination and delivery support.
NPP supports access to Rezdiffra for patients in Ahmedabad, working directly with treating specialists.
Patients in Kochi and across Kerala can access Rezdiffra through NPP's regulated import pathway.
NPP coordinates access to Rezdiffra for patients in Chandigarh and the surrounding region.
Patients in Jaipur can access Rezdiffra through NPP with support from treating specialists.
NPP facilitates access to Rezdiffra for patients in Lucknow and across Uttar Pradesh.
Patients in Bhubaneswar can access Rezdiffra through NPP's coordinated import and delivery process.
NPP supports access to Rezdiffra for patients in Guwahati and across the Northeast region.
NPP also supports access for patients in other Indian cities not listed above — contact the team to check availability and timelines for your location.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 09 September 2026
Sources: FDA • CDSCO
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 09 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
